Loading
A phase 2 trial of vudalimab in ovarian cancer, endometrial cancer, cervical cancer and prostate cancer, run by Xencor, Inc., active and no longer recruiting.
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies is a phase 2 interventional study registered as NCT05032040 by Xencor, Inc., with 170 participants enrolled, started 2022-07-21 and due to reach its primary completion in 2025-10-15. Interventions recorded: vudalimab.
Shares ICON plc and the tag pipeline.
Shares Endometrial cancer, Cervical cancer, Ovarian cancer, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Prostate cancer and the tag pipeline.
Shares ICON plc and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Prostate cancer and the tag pipeline.